Intercept Pharmaceuticals Inc (ICPT) was Initiated by Cantor Fitzgerald to “Sell” and the brokerage firm has set the Price Target at $58. Cantor Fitzgerald advised their investors in a research report released on Jul 6, 2016.
Many Wall Street Analysts have commented on Intercept Pharmaceuticals Inc. Shares were Reiterated by Wedbush on Jun 1, 2016 to “Outperform” and Lowered the Price Target to $ 239 from a previous price target of $423 .Intercept Pharmaceuticals Inc was Downgraded by Morgan Stanley to ” Underweight” on Apr 8, 2016.
On the company’s financial health, Intercept Pharmaceuticals Inc reported $-5.17 EPS for the quarter, missing the analyst consensus estimate by $ -1.41 based on the information available during the earnings call on May 5, 2016. Analyst had a consensus of $-3.76.Analysts expectations of $ .64.During the same quarter in the previous year, the company posted $-1.78 EPS.
Intercept Pharmaceuticals Inc closed down -2.89 points or -1.97% at $143.47 with 4,36,744 shares getting traded on Tuesday. Post opening the session at $145.56, the shares hit an intraday low of $142.45 and an intraday high of $147.29 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on May 26, 2016, Lisa Bright (officer ) sold 251 shares at $137.50 per share price. According to the SEC, on May 4, 2016, Rachel Mcminn (Chief Strategy Officer) sold 130 shares at $147.49 per share price. On Apr 7, 2016, Mark Pruzanski (CEO & President) sold 708 shares at $130.76 per share price, according to the Form-4 filing with the securities and exchange commission.
Intercept Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Companys product candidate obeticholic acid (OCA) is a bile acid analog a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is also developing other products INT-767 and INT-777 for the treatment of fibrosis and type 2 diabetes. OCA has been tested in five placebo-controlled clinical trials including a completed Phase III clinical trial in patients with primary biliary cirrhosis (PBC) and two Phase II clinical trials in patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). OCA met the primary efficacy endpoint in each of these trials with statistical significance.